LifeStance Health Group Insider TPG Gp a LLC Sells $485M of Stock
TPG Gp a LLC sold 37,233,110 shares of LifeStance Health Group, Inc. at $13.02 a share, worth $485M in total on Nov 12, 2026. Shares held after the trade: 42,458,592 (-46.7%).
LifeStance Health Group Insider Ryan Pardo Sells $40.9M of Stock
Ryan Pardo sold 2,804,505 shares of LifeStance Health Group, Inc. at $14.58 a share, worth $40.9M in total on Nov 10, 2026. Shares held after the trade: 334,935 (-86.9%).
LifeStance Health Group Director Kenneth A. Burdick Sells $2.05M of Stock
Kenneth A. Burdick, Director, sold 141,589 shares of LifeStance Health Group, Inc. at $14.41 to $14.60 a share (average $14.51) in 2 transactions, worth $2.05M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,904,221 (-2.5%).
LifeStance Health Group COO Lisa K. Miller Sells $215K of Stock
Lisa K. Miller, COO, sold 14,663 shares of LifeStance Health Group, Inc. at $14.68 a share, worth $215K in total on Nov 11, 2026. Shares held after the trade: 251,904 (-5.5%).
LifeStance Health Group M&A Deal with Selling Stockholders
LifeStance Health Group, Inc. entered into an underwriting agreement for a secondary offering of 45,000,000 shares of common stock sold by existing stockholders. The company did not receive any proceeds from the sale, but it repurchased 2,000,000 of these shares from the underwriters as part of the transaction.
LifeStance Health Group reported a significant improvement in financial performance for the third quarter of 2026, with total revenue increasing to $455.9 million compared to $363.8 million in the prior year. The company achieved a net income of $22.4 million for the quarter, a substantial increase from $1.1 million in the same period of 2025, driven by strong growth in income from operations.
LifeStance Health Group reported Q3 2026 revenue of $455.9 million, a 25% increase year-over-year, driven by higher visit volumes and clinician growth. The company significantly improved profitability, reporting net income of $22.4 million compared to $1.1 million in the prior year, and raised its full-year 2026 revenue and Adjusted EBITDA guidance.
Term
Q3 2026
“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations. The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence.”
Teresa DeLuca, M.D., notified the Board of Directors of LifeStance Health Group, Inc. of her resignation from the Board and all committees, effective December 31, 2026. The company stated the resignation was not due to any disagreement with the company.